Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate With Vertebral Fracture as an Index -
Phase of Trial: Phase II/III
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Ibandronic acid (Primary) ; Risedronic acid
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms MOVER
- Sponsors Chugai Pharmaceutical; Taisho Pharmaceutical
- 15 Sep 2014 Subgroup analysis results presented at the 36th Annual Meeting of the American Society for Bone and Mineral Research.
- 05 Apr 2014 Results presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
- 06 Oct 2013 Tolerability results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History